A trial looking at chemotherapy and rituximab for people with diffuse large B cell non Hodgkin lymphoma or Burkitt's lymphoma (R-CODOX-M/IVAC for DLBCL or BL)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

High grade lymphoma
Non-Hodgkin lymphoma




Phase 2

This trial is looking at a new combination of chemotherapy drugs with rituximab for 2 types of non Hodgkin lymphoma (NHL). These are called diffuse large B cell lymphoma and Burkitt's lymphoma. The treatment is called R-CODOX-M/IVAC for short.

This trial is for people who have a medium or high risk of their lymphoma coming back after treatment. The standard treatment for diffuse large B cell NHL is a combination of chemotherapy and a type of monoclonal antibody called rituximab. This is called R-CHOP. It is a successful treatment for many. But some people’s lymphoma comes back or continues to grow despite treatment. Doctors want to improve on this and to control the lymphoma for longer.

CODOX-M/IVAC includes the chemotherapy drugs cyclophosphamide, doxorubicin, vincristine, methotrexate, etoposide, ifosfamide and cytarabine. Trials have already shown that this combination of drugs works well for people with Burkitt’s lymphoma. In this trial, researchers want to see if adding rituximab (R-CODOX-M/IVAC) will improve the treatment for Burkitt's lymphoma. And they think it may work well for diffuse large B cell lymphoma too.

This trial aims to find out how well R-CODOX-M/IVAC works for people with diffuse large B cell NHL and Burkitt's lymphoma. It will also look at the side effects to find out how this treatment affects their quality of life.

Who can enter

You can enter this trial if you

  • Have recently been diagnosed with diffuse large B cell lymphoma or Burkitt's lymphoma
  • Have a protein called CD20 on your lymphoma cells ('CD20 positive' NHL) - your doctor will be able to tell you if this applies to you
  • Have stage 2, 3 or 4 NHL and your doctor thinks that you are at a medium (intermediate) or high risk of your lymphoma coming back after treatment
  • Are at least 18 years old but less than 66 years old
  • Have satisfactory blood test results
  • Are well enough to have treatment
  • Are willing to use reliable contraception during the trial if there is any chance you or your partner could become pregnant

You cannot enter this trial if you

  • Have already had chemotherapy or radiotherapy for your lymphoma
  • Have already had any treatment as part of a trial for your lymphoma
  • Have T cell lymphoma Open a glossary item
  • Have had a low grade lymphoma in the past
  • Have heart failure or uncontrolled angina, or have had either of these in the past
  • Are unable to have the chemotherapy drugs doxorubicin or vincristine for medical reasons
  • Have any serious illness that is not controlled properly with treatment
  • Have, or have had, any other type of cancer (apart from non-melanoma skin cancer or carcinoma in situ of the cervix) in the last 10 years
  • Are hepatitis B, hepatitis C or HIV positive (some people with Burkitt's lymphoma who are HIV positive may be able to take part - the trial doctor can discuss this with you)

Trial design

This phase 2 trial will recruit 150 people with diffuse large B cell NHL or Burkitt's lymphoma. All patients will have treatment with R-CODOX-M/IVAC (the letters refer to the different drug names).

During the first 2 weeks of your treatment you will have rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate (R-CODOX-M). You will have these drugs through a drip into a vein.

You will also have cytarabine injected into the fluid around your spinal cord. This is called an intrathecal injection and goes into the lower part of your back. It helps to treat or prevent lymphoma spread to the central nervous system Open a glossary item. After these 2 weeks of treatment, you have no treatment for the next 2 weeks. This 4 week period is called a cycle of treatment.

In week 5 you start R-IVAC treatment. You will have rituximab, etoposide, ifosfamide and cytarabine through a drip into a vein. If you have high risk lymphoma, you will also have cytarabine into the spinal fluid as before. After this week of treatment you then have no treatment for the next 3 weeks. This 4 week period is your second cycle of treatment.

You then have a further cycle of R-CODOX-M, followed by another cycle of R-IVAC. So you have 4 cycles of treatment in total over about 4 months.

After your 4th cycle of treatment you will have 2 more doses of rituximab. You have these about 3 weeks and 6 weeks after your last cycle.

During every cycle you will also have an injection of G-CSF (granulocyte colony stimulating factor). This is an injection just under your skin either into your stomach, arm or thigh. It helps your bone marrow to make new white blood cells. If your bone marrow recovers after each treatment, you are more likely to have your next cycle on time.

The treatment schedule in this trial is quite complicated. For each cycle your doctor or nurse will explain in detail when you have each drug and how often.

Hospital visits

Before you start your treatment, a doctor will examine you and you will have various tests. These tests may include

  • Bone marrow test
  • Blood tests
  • CT scan of your neck, chest, tummy (abdomen) Open a glossary item and pelvis Open a glossary item
  • An ECG Open a glossary item (heart trace)
  • A heart ultrasound (echocardiogram Open a glossary item) or MUGA Open a glossary item scan

During your treatment you will probably stay in hospital for about 2 weeks for each cycle of treatment. Or sometimes longer if you are unwell. You have blood tests before and during each cycle of treatment.

After your treatment has finished you see a doctor every month for the first 4 months, then every 2 months for the first year. These appointments gradually become less often. They will be 6 monthly after year 4, then yearly after that.

You have a CT scan at the end of your treatment, another after 4 months and another 1 year later.

The trial doctors will ask for a sample of the lymphoma that was taken when you were first diagnosed. This will be stored and may be used for future research. This part of the trial is optional. You do not have to agree to this if you don’t want to. You will still be able to take part in the trial.

Side effects

All treatment have side effects. The most common side effects of the drugs used in this trial include

You can read more about the side effects of cyclophosphamide, doxorubicin, vincristine, methotrexte, etoposide, ifosfamide, cytarabine and rituximab on CancerHelp UK. The trial doctor or nurse will explain side effects to you in more detail.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Andrew McMillan

Supported by

Experimental Cancer Medicine Centre (ECMC)
Haematology Trials Group
NIHR Clinical Research Network: Cancer

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 736

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

Currently rated: 2 out of 5 based on 1 vote
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page